title: Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis.
abstract: Patients with second-stage human African trypanosomiasis treated with eflornithine (n = 251) in 2003 in Kiri, southern Sudan, had an adjusted relative risk of death of 0.2 and experienced significantly fewer cutaneous and neurological adverse effects than did patients who were treated with melarsoprol in 2001 and 2002 (n = 708).
authors.affiliation: Médecins Sans Frontières, Geneva University Hospitals, Geneva, Switzerland. francois.chappuis@hcuge.ch
authors.forename: François
authors.initials: F
authors.lastname: Chappuis
authors.forename: Nitya
authors.initials: N
authors.lastname: Udayraj
authors.forename: Kai
authors.initials: K
authors.lastname: Stietenroth
authors.forename: Ann
authors.initials: A
authors.lastname: Meussen
authors.forename: Patrick A
authors.initials: PA
authors.lastname: Bovier
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D000518:Eflornithine / Q000009:adverse effects* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008549:Melarsoprol / Q000009:adverse effects* / Q000627:therapeutic use*; D013397:Sudan / Q000453:epidemiology; D014344:Trypanocidal Agents / Q000009:adverse effects / Q000627:therapeutic use; D014353:Trypanosomiasis, African / Q000188:drug therapy* / Q000401:mortality
chemical_list: D014344:Trypanocidal Agents; D008549:Melarsoprol; D000518:Eflornithine